To learn how VIBATIV may help treat your patients with HABP/VABP or cSSSI, use the tool below..
Think about a patient you’re currently treating.
Patient with HABP and vancomycin MIC ≤1 μg/mL
Immunocompromised patient with cSSSI
Elderly patient with HABP due to a recurrent S. aureus infection
Patient with VABP requiring <7 days of therapy
Patient with cSSSI who is able to transition to outpatient treatment
Patient with HABP taking an SSRI and hypoglycemic agents for type 2 diabetes
Patient with VABP and complicating factors
Patient with cSSSI and recurrent S. aureus infection
Patient with HABP who requires high doses of vancomycin
Patient with HABP and chronic obstructive pulmonary disease (COPD)
Overweight patient with cSSSI who requires an IV antibiotic
stephanie d.
Not an actual patient.For illustrative purposes only.
Age 56, Nurse
case history
- 56-year-old female presented with severe unstable angina
- Social history
- Patient is a nurse with increased risk for MRSA colonization
- Prior medical history
- Insulin-dependent diabetes mellitus
- Hypertension
- Patient was stabilized in the ER but experienced continuing angina; required percutaneous coronary intervention to implant 2 stents. During the procedure, patient had an episode of aspiration associated with conscious sedation
- After being discharged 1 day postprocedure, developed fever of 39.5°C with white blood cell count increased to 12,000/mm3 on day 4
Diagnostic evaluation and initial treatment
- Chest X-ray revealed right mid-lung infiltrate with some changes in the right lower lobe
- Expectorated sputum demonstrated Gram-positive cocci in clusters
- Started on ceftriaxone and vancomycin
1 g q12h - 48 hours later, low-grade fever and leukocytosis persist
- Infection confirmed to be MRSA with a vancomycin MIC >1 μg/mL
VIBATIV may help patients like Stephanie
- VIBATIV demonstrated efficacy in vancomycin MICs ≥1 μg/mL1
- VIBATIV demonstrated high in vitro potency against MRSA, including strains with reduced susceptibility to vancomycin2-4
- VIBATIV is a lipoglycopeptide with bactericidal activity and a dual mechanism of action against Gram-positive bacteria2,3
Carlos k.
Not an actual patient.For illustrative purposes only.
Age 44, Accountant
case history
- 44-year-old male presented to outpatient oncology center 3 days ago with erythema around chemotherapy port
- Port was removed
- Prescribed trimethoprim/sulfamethoxazole orally
- Prior medical history
- Diagnosed with acute lymphoblastic leukemia 1 month ago
- Currently receiving his first cycle of an immunosuppressive chemotherapy regimen (hyper-CVAD) that includes hyper-fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, and rituximab, which was initiated 16 days ago
- Patient presented to ER with an apparent port-site abscess with purulent drainage and a temperature of 38.8°C
Diagnostic evaluation and initial treatment
- Culture of pus from wound revealed Gram-positive cocci, confirming MRSA infection
- Patient is pancytopenic
- Started on vancomycin and piperacillin/tazobactam to address the onset of septic shock; showing no signs of improvement (change in drainage) after 48 hours
VIBATIV may help patients like Carlos
- VIBATIV is indicated for both MRSA and MSSA in cSSSI1
- VIBATIV demonstrated efficacy against MSSA2
- VIBATIV levels remain at least an order of magnitude above the MIC90 for MRSA over the once-daily dosing period1,2
- VIBATIV reduced the CFU/mL of MRSA within 4 hours1,2
Eddie R.
Not an actual patient.For illustrative purposes only.
Age 78, Barber
case history
- 78-year-old male presented to the ER complaining of 4 days of cough accompanied by fever, chills, and difficulty breathing
- Prior medical history
- Developed HABP due to MRSA after admittance for chest pain 3 weeks ago; patient was treated with two 8-day courses of vancomycin
- Patient was discharged to physical rehabilitation center
- Readmitted with temperature of 39°C, tachycardia (110 bpm), and tachypnea (24 breaths/min)
Diagnostic evaluation and initial treatment
- Patient has diffuse crackles in the bases of both lungs
- Patient started on empiric vancomycin
1 g q12h in ER for suspected unresolved MRSA HABP - Culture results not yet available; showing no improvement, and ongoing clinical instability and repeated exposures to vancomycin raise concerns
VIBATIV may help patients like Eddie
- In clinical trials, VIBATIV demonstrated cure rates against any single Gram-positive infection in patients with HABP/VABP that were statistically significantly higher than vancomycin1,2
- VIBATIV demonstrated cure rates similar to vancomycin in clinically meaningful subgroups of patients with HABP/VABP, including1:
- VABP
- Concomitant bacteremia
- Age ≥65 years
- Baseline CPIS score >6
- APACHE II score ≥20
Don N.
Not an actual patient.For illustrative purposes only.
Age 56, CEO
case history
- 56-year-old male presented to the ER after experiencing acute stroke
- Patient required prolonged stay in ICU; mechanical ventilation required; aspiration noted on admission
- Social history
- Long-term tobacco use
- Prior medical history includes repeat episodes of thrombocytopenia and anemia
- After 3 days of ventilation, patient has a temperature of 39.6°C, blood pressure of 90/40 mm Hg, and pulse oximetry of 84%; thick, tan secretions are coming from the endotracheal tube
Diagnostic evaluation and initial treatment
- Sputum culture is not definitive, but shows sign of both Gram-positive and Gram-negative organisms, including
S. aureus - Started on vancomycin 1 g q12h plus gentamicin
- Has increasing ventilatory requirements and increased opacification on CXR after 3 days of therapy
VIBATIV may help patients like Don
- VIBATIV has demonstrated efficacy in patients with VABP1
- Patients in VIBATIV clinical trials who received extended therapy with VIBATIV experienced similar safety results as those who did not2
- VIBATIV is recommended for 7 to 21 days of therapy in patients with HABP/VABP2
Cheryl K.
Not an actual patient.For illustrative purposes only.
Age 52, Social Worker
case history
- 52-year-old female admitted to hospital for right hip replacement surgery
- On postoperative day 4, developed fever of 38.5°C with white blood cell count increased to 13,000/mm3
- Infection appears localized to soft tissue only; no direct connection with hardware
- Prior medical history
- Taking selective serotonin reuptake inhibitor for depression
Diagnostic evaluation and initial treatment
- Pre-operative screening positive for MRSA
- Patient started on vancomycin 1 g q12h
- After 2 days of treatment, the patient is ready for discharge
- Patient would benefit from a once-daily treatment for ongoing therapy
VIBATIV may help patients like Cheryl
- VIBATIV has demonstrated efficacy in cSSSI1
- Once-daily VIBATIV requires no therapeutic drug-level monitoring2
- VIBATIV has complications of treatment that are familiar to physicians accustomed to treating with vancomycin1
Ashley J.
Not an actual patient.For illustrative purposes only.
Age 44, English Teacher
case history
- 44-year-old female presented in the ER with multiple facial fractures, closed head injury, and pulmonary contusion following a motor vehicle accident
- Admitted to the hospital for immediate surgery
- Prior medical history
- Type 2 diabetes mellitus, treated with metformin
- Taking a selective serotonin reuptake inhibitor (SSRI) for depression
- On postoperative day 3, developed fever of 38.5oC, white blood cell count increased to 14,000/mm3, tachycardia (110 bpm)
Diagnostic evaluation and initial treatment
- Chest X-ray reveals possible changes to left lobe
- Sputum cultures positive for S. aureus
- Patient started on vancomycin 1 g q12h
- After 48 hours, patient is clinically worsening
VIBATIV may help patients like Ashley
- VIBATIV has no known interactions with SSRIs1
- VIBATIV is a once-daily antibiotic that requires no therapeutic drug-level monitoring1
- VIBATIV has potent in vitro bactericidal activity against MRSA and MSSA isolates1,2
- VIBATIV has demonstrated efficacy in multiple subgroup analyses3
Thomas J.
Not an actual patient.For illustrative purposes only.
Age 74, Retired Police Officer
case history
- 74-year-old male presented in the ER after experiencing respiratory failure at nursing home
- Patient admitted to the ICU and required intubation and prolonged mechanical ventilation
- Four days after trach placement, patient developed a fever of 39°C with white blood cell count increased to 16,000/mm3
- Has a long-standing PICC line in place from SNF
- Prior medical history
- Moderate chronic obstructive pulmonary disease treated with nebulized albuterol sulfate and ipratropium bromide
Diagnostic evaluation and initial treatment
- Patient has concomitant bacteremia with seeding of PICC line; APACHE II score of 22; CPIS score of 7
- Sputum culture confirms infection with MRSA
- Patient was started on vancomycin 1 g q12h
- Patient is not improving while VABP and bacteremia persist after 48 hours
VIBATIV may help patients like Thomas
- VIBATIV demonstrated cure rates similar to vancomycin in clinically meaningful subgroups of patients with HABP/VABP, including1:
- VABP
- Concomitant bacteremia
- Age ≥65 years
- Baseline CPIS score >6
- APACHE II score ≥20
- VIBATIV demonstrated potency against various MRSA isolates
Mary C.
Not an actual patient.For illustrative purposes only.
Age 82, Retired
case history
- Long-term care resident, mostly bedridden
- Admitted to hospital 6 months ago with a severe wound infection and associated cellulitis in the left upper leg
- Wound was treated with incision, drainage, and 8 weeks of vancomycin and daptomycin
- Discharged to a physical rehabilitation center
- Currently readmitted with erythema of the right buttock over 48 hours
Diagnostic evaluation and initial treatment
- No purulent drainage, exudate, or abscess in the buttock
- No evidence of joint or bursa involvement
- Treated empirically with vancomycin
20 mg/kg IV q12h - No improvement is seen after 72 hours
- Last culture at long-term facility had MRSA MIC to vancomycin at >2 μg/mL and MIC to daptomycin at 4 μg/mL
VIBATIV may help patients like Mary
- In clinical trials, VIBATIV demonstrated statistically significantly higher cure rates vs vancomycin in patients with cSSSI who had normal renal status1
- VIBATIV demonstrated high in vitro potency against MRSA, including strains with reduced susceptibility to vancomycin2-4
Ryan M.
Not an actual patient.For illustrative purposes only.
Age 22, Student and
Nursing Home Aide
case history
- 22-year-old male who works as an aide in a nursing home presented in the ER with multiple lower extremity fractures from an accident
- Patient was admitted for surgery
- Prior medical history
- Patient was healthy prior to accident
- Patient had normal renal status at hospitalization, with above-average creatinine clearance
- On postoperative day 4, developed fever of 38.9°C with white blood cell count increased to 12,000/mm3
Diagnostic evaluation and initial treatment
- Sputum cultures were positive for MRSA
- Despite increasing doses of q8h vancomycin totaling over 3 g/day, infection is not resolving and patient is developing thrombophlebitis
VIBATIV may help patients like Ryan
- VIBATIV has activity in organisms with reduced susceptibility to vancomycin1,2
- VIBATIV levels remain at least an order of magnitude above MIC90 for MRSA over the once-daily dose period3,4
- In clinical trials, VIBATIV demonstrated cure rates against any single Gram-positive infection in patients with HABP/VABP that were statistically significantly higher than vancomycin
Anna L.
Not an actual patient.For illustrative purposes only.
Age 67, Retired
case history
- 67-year-old female presented to the ER complaining of 24-hour history of fever and chills, with an episode of rigors last night
- Prior medical history
- COPD treated with combination steroid/long-acting beta-agonist inhaler, tiotropium bromide, and albuterol as needed
- Patient has experienced frequent COPD exacerbations requiring hospitalization; the most recent was 2 weeks ago
- Patient has had a prior case of MRSA pneumonia treated with vancomycin
- Social history
- Moderate alcohol use; 2 pack/day smoking habit since mid-20s
- Patient complains of increased dyspnea and has been using her inhaler almost constantly
- Patient admits to a productive cough, but is not sure if it is different than her normal “smoker’s cough”
- Patient has a blood pressure of 168/92 mm Hg, a pulse of 128 bpm, a respiratory rate of 32 breaths/min, and pulse oximetry of 87%
Diagnostic evaluation and initial treatment
- Patient is placed on 4 liters of O2 and given an albuterol solution via nebulizer
- Chest X-ray reveals a right lower lobe infiltrate
- White blood cell count 17,000/mm3
- Gram stain indicates presence of both Gram-positive and Gram-negative organisms
VIBATIV may help patients like Anna
- VIBATIV demonstrated high in vitro potency against MRSA, including strains with reduced susceptibility to vancomycin1-3
- In clinical trials, VIBATIV demonstated cure rates against any single Gram-positive infection in patients with HABP/VABP that were statistically significantly higher than vancomycin4,5
Anthony T.
Not an actual patient.For illustrative purposes only.
Age 45, Lawyer
case history
- 45-year-old male presented to a primary care physician 3 days ago with a painful lesion on the right leg
- A large abscess was present on the upper anterior aspect of the right thigh, with surrounding cellulitis and associated tender inguinal lymphadenopathy
- Patient was prescribed oral clindamycin 450 mg q6h
- Prior medical history
- Allergy to β-lactam antibiotics
- BMI = 30
- Non–insulin-dependent diabetes mellitus
- Hypertension
- Presented to the ER with temperature of 38.8°C, rigors, and severe pain
Diagnostic evaluation and initial treatment
- Underwent incision and drainage of the abscess
- Treated empirically with vancomycin
20 mg/kg IV q12h - No improvement in lesion size or degree of drainage is seen after 48 hours
- Culture of pus confirms MSSA infection with a vancomycin MIC >1 μg/mL
VIBATIV may help patients like Anthony
- VIBATIV has demonstrated efficacy in cSSSI1
- VIBATIV demonstrated potency against various MRSA isolates2,3
- Once-daily VIBATIV has weight-based dosing and requires no therapeutic drug-level monitoring2
- VIBATIV levels remain at least an order of magnitude above the MIC90 for MRSA over the once-daily dosing period2